Alacrity Biosciences has announced positive results from a Phase II study of its treatment for dry eye, ALTY-0501.
Alacrity Biosciences has announced positive results from a Phase II study of its treatment for dry eye, ALTY-0501.
ALTY-0501 is a proprietary topical formulation of 0.025% doxycycline in a non-antimicrobial dose, which acts to inhibit matrix metalloproteinase-9 (MMP-9). By inhibiting MMP-9, ALTY-0501 is thought to prevent the disruption of the epithelial barrier on the ocular surface.
The Phase II double-masked, randomized, parallel-group study enrolled 160 subjects to assess the safety and efficacy of the drug. Patients with dry eye were exposed to a controlled adverse environment on day one and asked to self-administer ALTY-0501 eye drops or vehicle eye drops four times a day. Patients were re-exposed to the controlled adverse environment on days 28 and 56. Environmental damage was assessed using fluorescein staining and symptoms were measured daily through patient diaries throughout the study period.
Patients who received ALTY-0501 demonstrated statistically significantly lower scores after fluorescein staining, following exposure, than the control group on day 28 (p<0.05). The drug also demonstrated statistically significant advantages compared with vehicle in the patient diary scores. Specifically, patient diary scores reflected statistically significantly lower scores for the symptoms of burning (p<0.0001), stinging (p<0.0001) and grittiness (p<0.0001) in the active treatment group.
Alacrity plans to initiate Phase III trials early in 2008.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.